一种蛋白酶体抑制剂,适用于与来那度胺和地塞米松联合用于治疗既往接受过至少一次治疗的多发性骨髓瘤患者。
相关产品
¥2,015.00
≈ ₭6,246,500
≈ ₭6,246,500
0 out of 5
¥639.52
≈ ₭1,982,500
≈ ₭1,982,500
0 out of 5
¥393.55
≈ ₭1,220,000
≈ ₭1,220,000
0 out of 5
¥19.68
≈ ₭61,000
≈ ₭61,000
0 out of 5
¥196.77
≈ ₭610,000
≈ ₭610,000
0 out of 5
¥10,515.00
≈ ₭32,596,500
≈ ₭32,596,500
0 out of 5
¥590.32
≈ ₭1,830,000
≈ ₭1,830,000
0 out of 5
¥3,815.00
≈ ₭11,826,500
≈ ₭11,826,500
0 out of 5














评价
目前还没有评价